Comparison 1. Cabergoline versus Bromocriptine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 UPDRS ADL scores (part II)			Other data	No numeric data
2 UPDRS motor scores (part III)			Other data	No numeric data
3 Hoehn and Yahr stage			Other data	No numeric data
4 Schwab and England scale			Other data	No numeric data
5 Clinicians global impression (number much or very much improved)	3	784	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.01 [0.76, 1.33]
6 Levodopa dose reduction (mg)	4	909	Mean Difference (IV, Fixed, 95% CI)	6.00 [‐21.79, 33.79]
7 Off time reduction (hours)	4	612	Mean Difference (IV, Fixed, 95% CI)	0.29 [‐0.10, 0.68]
8 Adverse events ‐ Nausea	5	1048	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.99 [0.73, 1.35]
9 Adverse events ‐ Postural hypotension	5	1048	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.74 [0.49, 1.11]
10 Adverse events ‐ Hallucinations	5	1048	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.34 [0.88, 2.06]
11 Adverse events ‐ Confusion	4	835	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.02 [1.09, 3.76]
12 Adverse event ‐ Dyskinesia	5	1048	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.57 [1.05, 2.35]
13 Adverse events ‐ Insomnia	5	1048	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.95 [0.58, 1.54]
14 Adverse events ‐ Sleep disorder	3	793	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.35 [0.82, 2.21]
15 Adverse events ‐ Vivid dreams	1	44	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.0 [0.06, 16.52]
16 Adverse events ‐ Somnolence	4	1006	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.97 [0.55, 1.73]
17 All cause withdrawal rate	5	1071	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.87 [0.63, 1.20]